Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday

Meir Medical Center150 enrolled

Overview

The purpose of the study is to provide information about the rate of response and persistence to drug therapies for osteoporosis. Another issue examined in this study refers to the preferences and concerns about future treatments in patients during "drug holiday".

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Osteoporosis

Interventions

Questionnaires about compliance and persistence with bisphosphonates treatmentOTHER

Eligibility

Sex: FEMALEMin age: 40 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women * Diagnosis of osteoporosis in the medical record * At least one prescription drug to treat osteoporosis in the last 5 years * Insured by "Clalit" Health Services * Hebrew-speaking capability and readiness to answer a questionnaire Exclusion Criteria: * Premenopausal women * No diagnosis of osteoporosis in the medical record * No treatment for osteoporosis in the last 5 years * Women who do not speak Hebrew or are unable to answer a questionnaire

Locations (1)

Meir medical center the clalit health care services group

Kfar Saba, Israel

Outcomes

Primary Outcomes

Compliance and persistence to osteoporosis drug therapy

Data collection will be done by questionnaires and from the medical record of the patient. The information collected will include: demographic information, measurements of bone density, additional information about the disease and treatment that the patient receives,prescription purchases and additional drugs the patient is taking (steroids, PPI's(Proton Pump Inhibitors) / H2 receptor antagonists and NSAIDs(Non Steroidal Anti Inflammatories)).

Time frame: Participants will be followed for the duration of their clinic visit, an average of 5 hours

Central Contacts

Pnina Rotman, M.D

CONTACT

972-57-7482609 Pnina.Rotman@clalit.org.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.